Recent Trends in Oral Anticoagulant Use and Post-Discharge Complications Among Atrial Fibrillation Patients with Acute Myocardial Infarction
Authors
Kundu, AmartyaDay, Kevin O.
Lessard, Darleen M.
Gore, Joel M.
Yu, Hong
Akhter, Mohammed W.
Fisher, Daniel Z.
Hayward, Robert M. Jr
Henninger, Nils
Kapoor, Alok
Yarzebski, Jorge L.
Goldberg, Robert J.
McManus, David D.
UMass Chan Affiliations
Department of NeurologyDepartment of Quantitative Health Sciences
Department of Medicine, Division of Cardiovascular Medicine
Document Type
Journal ArticlePublication Date
2018-02-28Keywords
AnticoagulationAtrial Fibrillation
Epidemiology
Outcomes
Cardiology
Cardiovascular Diseases
Clinical Epidemiology
Epidemiology
Health Services Administration
Metadata
Show full item recordAbstract
Background: Atrial fibrillation (AF) is a common complication of acute myocardial infarction (AMI).The CHA2DS2VAScand CHADS2risk scoresare used to identifypatients with AF at risk for strokeand to guide oral anticoagulants (OAC) use, including patients with AMI. However, the epidemiology of AF, further stratifiedaccording to patients' risk of stroke, has not been wellcharacterized among those hospitalized for AMI. Methods: We examined trends in the frequency of AF, rates of discharge OAC use, and post-discharge outcomes among 6,627 residents of the Worcester, Massachusetts area who survived hospitalization for AMI at 11 medical centers between 1997 and 2011. Results: A total of 1,050AMI patients had AF (16%) andthe majority (91%)had a CHA2DS2VAScscore > 2.AF rates were highest among patients in the highest stroke risk group.In comparison to patients without AF, patients with AMI and AF in the highest stroke risk category had higher rates of post-discharge complications, including higher 30-day re-hospitalization [27 % vs. 17 %], 30-day post-discharge death [10 % vs. 5%], and 1-year post-discharge death [46 % vs. 18 %] (p < 0.001 for all). Notably, fewer than half of guideline-eligible AF patients received an OAC prescription at discharge. Usage rates for other evidence-based therapies such as statins and beta-blockers,lagged in comparison to AMI patients free from AF. Conclusions: Our findings highlight the need to enhance efforts towards stroke prevention among AMI survivors with AF.Source
J Atr Fibrillation. 2018 Feb 28;10(5):1749. doi: 10.4022/jafib.1749. eCollection 2018 Feb. Link to article on publisher's site
DOI
10.4022/jafib.1749Permanent Link to this Item
http://hdl.handle.net/20.500.14038/46752PubMed ID
29988239Notes
Full author list omitted for brevity. For the full list of authors, see article.
Related Resources
Rights
Journal of Atrial Fibrillation is an open access journal according to http://jafib.com/open_access.php. The license used is the Creative Commons Attribution 2.5 Generic license.ae974a485f413a2113503eed53cd6c53
10.4022/jafib.1749
